Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)

This study is testing whether adding selinexor — a drug that blocks cancer cells from exporting certain protective proteins — to the standard R-CHOP chemotherapy regimen improves outcomes for people with newly diagnosed diffuse large B-cell lymphoma (DLBCL) that carries a TP53 mutation. TP53 mutations make this lymphoma more difficult to treat with standard therapy. **You may be eligible if...** - You are 18–80 years old - You have a newly confirmed diagnosis of DLBCL with a TP53 mutation (your doctor can test for this) - You have not had prior systemic (whole-body) lymphoma treatment (prior local radiation alone is acceptable) - You have measurable disease visible on scans **You may NOT be eligible if...** - You have received prior chemotherapy or immunotherapy for lymphoma - Your TP53 mutation has not been confirmed - You have significant liver, kidney, or heart problems that would make R-CHOP or selinexor unsafe Talk to your doctor to see if this trial is right for you.